Amphastar Pharmaceuticals, Inc.
AMPH
$17.50
-$0.95-5.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 720.53M | 719.89M | 723.76M | 720.74M | 725.71M |
| Total Other Revenue | -- | -- | -455.00K | 1.94M | 4.95M |
| Total Revenue | 720.53M | 719.89M | 723.31M | 722.68M | 730.66M |
| Cost of Revenue | 379.40M | 363.83M | 366.27M | 362.35M | 361.65M |
| Gross Profit | 341.13M | 356.06M | 357.04M | 360.33M | 369.01M |
| SG&A Expenses | 108.80M | 106.71M | 103.32M | 99.27M | 97.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 580.69M | 556.38M | 550.26M | 541.01M | 535.96M |
| Operating Income | 139.84M | 163.50M | 173.04M | 181.67M | 194.70M |
| Income Before Tax | 102.81M | 123.62M | 135.67M | 161.84M | 172.75M |
| Income Tax Expenses | 23.59M | 25.53M | 24.04M | 27.13M | 31.12M |
| Earnings from Continuing Operations | 79.23 | 98.09 | 111.63 | 134.71 | 141.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.23M | 98.09M | 111.63M | 134.71M | 141.63M |
| EBIT | 139.84M | 163.50M | 173.04M | 181.67M | 194.70M |
| EBITDA | 197.27M | 220.20M | 228.83M | 236.73M | 248.30M |
| EPS Basic | 1.71 | 2.10 | 2.36 | 2.81 | 2.93 |
| Normalized Basic EPS | 1.70 | 1.96 | 2.10 | 2.11 | 2.23 |
| EPS Diluted | 1.66 | 2.03 | 2.26 | 2.67 | 2.76 |
| Normalized Diluted EPS | 1.65 | 1.91 | 2.02 | 2.01 | 2.10 |
| Average Basic Shares Outstanding | 184.65M | 186.97M | 189.04M | 191.19M | 193.14M |
| Average Diluted Shares Outstanding | 189.43M | 192.86M | 197.01M | 201.19M | 205.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |